Literature DB >> 20685860

Severe obesity is associated with symptomatic presentation, higher parathyroid hormone levels, and increased gland weight in primary hyperparathyroidism.

Mohamed Abdelgadir Adam1, Brian R Untch, Melissa E Danko, Sandra Stinnett, Darshana Dixit, James Koh, Jeffrey R Marks, John A Olson.   

Abstract

CONTEXT: A relationship between primary hyperparathyroidism (PHPT) and obesity has been observed but is incompletely understood. Furthermore, obesity has been associated with vitamin D deficiency, suggesting that the three conditions may be linked.
OBJECTIVE: We hypothesized that PHPT in morbidly obese patients is more severe and that the difference may be explained by vitamin D deficiency. DESIGN AND SETTING, PARTICIPANTS, AND OUTCOME MEASURES: Records of 196 patients with surgically treated PHPT and known body mass index (BMI) were examined. Patients were stratified into three BMI groups: group I (nonobese), BMI < 25 kg/m(2) (n = 54); group II (non-severely obese), BMI 25-34 kg/m(2) (n = 102); and group III (severely obese), BMI 35 kg/m(2) or greater (n = 40).
RESULTS: Preoperative PTH levels were higher in group ΙΙΙ compared with group Ι (181 ± 153 vs. 140 ± 80 pg/ml, p = 0.04). Group III patients had larger tumors on average compared with group I (1.8 ± 1.5 vs. 1.04 ± 1.5 g, P = 0.0002). In group III, BMI positively correlated with parathyroid tumor weight (r = 0.5, P = 0.002). Postoperative PTH was higher in group III compared with group Ι (61 ± 41 vs. 44 ± 28 pg/ml, P = 0.02). There was higher frequency of depression, musculoskeletal symptoms, weakness, and gastroesophageal reflux disease in group III patients.
CONCLUSIONS: BMI positively correlated with parathyroid tumor weight independent of vitamin D. Severely obese patients have larger parathyroid tumor weight, higher pre- and postoperative PTH, and greater symptoms.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20685860      PMCID: PMC3205600          DOI: 10.1210/jc.2010-0666

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  39 in total

Review 1.  Clinical spectrum of primary hyperparathyroidism.

Authors:  J P Bilezikian; S J Silverberg
Journal:  Rev Endocr Metab Disord       Date:  2000-11       Impact factor: 6.514

Review 2.  Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century.

Authors:  John P Bilezikian; John T Potts; Ghada El-Hajj Fuleihan; Michael Kleerekoper; Robert Neer; Munro Peacock; Jonas Rastad; Shonni J Silverberg; Robert Udelsman; Samuel A Wells
Journal:  J Clin Endocrinol Metab       Date:  2002-12       Impact factor: 5.958

3.  Parathyroid function in human vitamin D deficiency and vitamin D deficiency in primary hyperparathyroidism.

Authors:  G A Lumb; S W Stanbury
Journal:  Am J Med       Date:  1974-06       Impact factor: 4.965

4.  Effect of vitamin D nutrition on parathyroid adenoma weight: pathogenetic and clinical implications.

Authors:  D S Rao; M Honasoge; G W Divine; E R Phillips; M W Lee; M R Ansari; G B Talpos; A M Parfitt
Journal:  J Clin Endocrinol Metab       Date:  2000-03       Impact factor: 5.958

5.  Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults.

Authors:  Eugenia E Calle; Carmen Rodriguez; Kimberly Walker-Thurmond; Michael J Thun
Journal:  N Engl J Med       Date:  2003-04-24       Impact factor: 91.245

6.  Serum parathyroid hormone level is associated with body mass index. The 5th Tromsø study.

Authors:  Elena Kamycheva; Johan Sundsfjord; Rolf Jorde
Journal:  Eur J Endocrinol       Date:  2004-08       Impact factor: 6.664

7.  Selective estrogen receptor modulators inhibit the effects of insulin-like growth factors in hyperparathyroidism.

Authors:  Chris Wong; Teresa Lai; Jeff M P Hilly; Claire E H Stewart; John R Farndon
Journal:  Surgery       Date:  2002-12       Impact factor: 3.982

8.  Obesity is associated with increased parathyroid hormone levels independent of glomerular filtration rate in chronic kidney disease.

Authors:  Georges Saab; Adam Whaley-Connell; Samy I McFarlane; Suying Li; Shu-Cheng Chen; James R Sowers; Peter A McCullough; George L Bakris
Journal:  Metabolism       Date:  2009-10-02       Impact factor: 8.694

9.  Preoperative normal level of parathyroid hormone signifies an early and mild form of primary hyperparathyroidism.

Authors:  Anders Bergenfelz; Pia Lindblom; Birger Lindergård; Stig Valdemarsson; Johan Westerdahl
Journal:  World J Surg       Date:  2003-04       Impact factor: 3.352

10.  Calcium metabolism in the morbidly obese.

Authors:  Nahid Hamoui; Gary Anthone; Peter F Crookes
Journal:  Obes Surg       Date:  2004-01       Impact factor: 4.129

View more
  7 in total

1.  The impact of obesity on the presentation of primary hyperparathyroidism.

Authors:  Hien Tran; Jacob S Grange; Beverley Adams-Huet; Fiemu E Nwariaku; Jennifer L Rabaglia; Stacey L Woodruff; Shelby A Holt; Naim M Maalouf
Journal:  J Clin Endocrinol Metab       Date:  2014-03-31       Impact factor: 5.958

Review 2.  Bone Remodeling and Energy Metabolism: New Perspectives.

Authors:  Francisco J A de Paula; Clifford J Rosen
Journal:  Bone Res       Date:  2013-03-29       Impact factor: 13.567

3.  Prevalence of cardiovascular risk factors in male and female patients with primary hyperparathyroidism.

Authors:  D Han; S Trooskin; X Wang
Journal:  J Endocrinol Invest       Date:  2011-07-12       Impact factor: 4.256

Review 4.  The intriguing connections of leptin to hyperparathyroidism.

Authors:  Stergios A Polyzos; Leonidas Duntas; Jens Bollerslev
Journal:  Endocrine       Date:  2017-07-20       Impact factor: 3.633

5.  Serum leptin, parathyroid hormone, 1,25-dihydroxyvitamin D, fibroblast growth factor 23, bone alkaline phosphatase, and sclerostin relationships in obesity.

Authors:  Elizabeth Grethen; Kathleen M Hill; RoseMarie Jones; Brenda M Cacucci; Christine E Gupta; Anthony Acton; Robert V Considine; Munro Peacock
Journal:  J Clin Endocrinol Metab       Date:  2012-02-22       Impact factor: 5.958

6.  Parathyroid hormone in surgery-induced weight loss: no glucometabolic effects but potential adaptive response to skeletal loading.

Authors:  Valeria Guglielmi; Alfonso Bellia; Paolo Gentileschi; Mauro Lombardo; Monica D'Adamo; Davide Lauro; Paolo Sbraccia
Journal:  Endocrine       Date:  2017-11-22       Impact factor: 3.633

7.  Parathyroid gland weight is associated with high density lipoprotein levels in patients with primary hyperparathyroidism.

Authors:  Aseel Al Dayyeni; Amar Mahdi; Yuling He; Stanley Z Trooskin; Lingqiong Meng; Xiangbing Wang
Journal:  J Clin Transl Endocrinol       Date:  2019-11-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.